AHR and multiple sclerosis: In an animal model of multiple sclerosis (autoimmune encephalomyelitis), it has been shown that AhR may be a therapeutic target in multiple sclerosis too: a knockdown of AhR worsens disease signs, whereas AhR activation by such AhR agonists as TCDD, indole-3-carbinol, or diindolylmethane slows the progression of experimental allergic encephalomyelitis, owing to the overexpression of Forkhead Box P3, greater numbers of anti-inflammatory regulatory T cells, and the attenuation of proinflammatory expansion of T helper 17 (Th17) cells [246,248,249].